Literature DB >> 15006599

Monoclonal antibodies produced by muscle after plasmid injection and electroporation.

Torunn Elisabeth Tjelle1, Alexandre Corthay, Elin Lunde, Inger Sandlie, Terje E Michaelsen, Iacob Mathiesen, Bjarne Bogen.   

Abstract

Antibodies are useful for the treatment of a variety of diseases. We here demonstrate that mouse muscle produced monoclonal antibodies (mAb) after a single injection of immunoglobulin genes as plasmid DNA. In vivo electroporation of muscle greatly enhanced antibody production. For chimeric antibodies, levels of 50-200 ng mAb/ml serum were obtained but levels declined after 7-14 days due to an immune response against the xenogeneic parts of the antibody. By contrast, fully mouse antibodies persisted in serum for at least 7 months. mAb produced by the muscle had correct structure, specificity, and biological effector functions. The findings were extended to a larger animal, the sheep, in which mAb serum levels of 30-50 ng/ml were obtained. Sustained levels of serum mAb, induced by single injection of Ig genes and electroporation of muscle cells, may offer significant advantages in the treatment of human diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15006599     DOI: 10.1016/j.ymthe.2003.12.007

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  24 in total

1.  2A peptide-based, lentivirus-mediated anti-death receptor 5 chimeric antibody expression prevents tumor growth in nude mice.

Authors:  Meng Li; Yaomin Wu; Yuhe Qiu; Zhenyu Yao; Shilian Liu; Yanxin Liu; Juan Shi; Dexian Zheng
Journal:  Mol Ther       Date:  2011-09-20       Impact factor: 11.454

2.  Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab.

Authors:  Kar Muthumani; Seleeke Flingai; Megan Wise; Colleen Tingey; Kenneth E Ugen; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2013-09-17       Impact factor: 3.452

3.  Immunotherapy perspectives in the new era of B-cell editing.

Authors:  Natsuko Ueda; Marine Cahen; Yannic Danger; Jérôme Moreaux; Christophe Sirac; Michel Cogné
Journal:  Blood Adv       Date:  2021-03-23

Review 4.  Gene-based vaccines and immunotherapeutic strategies against neurodegenerative diseases: Potential utility and limitations.

Authors:  Jeremy J Kudrna; Kenneth E Ugen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  Engineering humoral immunity as prophylaxis or therapy.

Authors:  Cailin E Deal; Alejandro B Balazs
Journal:  Curr Opin Immunol       Date:  2015-07-14       Impact factor: 7.486

6.  Generation of antibody-producing hybridomas following one single immunization with a targeted DNA vaccine.

Authors:  I Øynebråten; T-O Løvås; K Thompson; B Bogen
Journal:  Scand J Immunol       Date:  2012-04       Impact factor: 3.487

7.  Heterodimeric barnase-barstar vaccine molecules: influence of one versus two targeting units specific for antigen presenting cells.

Authors:  Heidi Cecilie Larsen Spång; Ranveig Braathen; Bjarne Bogen
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

8.  Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer.

Authors:  G Wang; J Qiu; R Wang; A Krause; J L Boyer; N R Hackett; R G Crystal
Journal:  Cancer Gene Ther       Date:  2010-05-07       Impact factor: 5.987

9.  Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models.

Authors:  Roberto Di Niro; Federica Ziller; Fiorella Florian; Sergio Crovella; Marco Stebel; Marco Bestagno; Oscar Burrone; Andrew R M Bradbury; Paola Secco; Roberto Marzari; Daniele Sblattero
Journal:  BMC Biotechnol       Date:  2007-08-01       Impact factor: 2.563

10.  Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells.

Authors:  Agnete B Fredriksen; Inger Sandlie; Bjarne Bogen
Journal:  Front Oncol       Date:  2012-10-30       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.